FDA approves oral anticonvulsant

Pharmaceutical company Lupin announced that the FDA has approved its abbreviated new drug application for anti-epileptic vigabatrin for oral solution, according to a press release.

A generic equivalent of Sabril (vigabatrin, Lundbeck), which is used to treat infantile spasms and refractory complex partial seizures in adults and children aged 10 years and older, vigabatrin was approved in a 500-mg dose.